Today, I'm going to be maintaining my buy rating. Medtronic's product portfolio and launches continued to show encouraging results in Q2. The company's balance sheet remains A-rated. Finally ...
Medtronic is capturing demand for its cutting-edge solutions, as recent product launches emerge to drive new growth. With the stock still trading at 26% below its 2021 peak, there's a sense that ...